Literature DB >> 25115305

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M Reck1, S Popat2, N Reinmuth1, D De Ruysscher3, K M Kerr4, S Peters5.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25115305     DOI： 10.1093/annonc/mdu199

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  259 in total

Review 1.  State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer.

Authors:  Alessandro Inno; Vincenzo Di Noia; Ettore D'Argento; Alessandra Modena; Stefania Gori
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 2.  Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.

Authors:  Grainne M O'Kane; Natasha B Leighl
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 3.  Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer.

Authors:  Consuelo Buttigliero; Valentina Bertaglia; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2016-12

4.  Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group.

Authors:  Ales Ryska; Rares Buiga; Albena Fakirova; Izidor Kern; Włodzimierz Olszewski; Lukas Plank; Sven Seiwerth; Erika Toth; Eri Zivka; Christiane Thallinger; Christoph Zielinski; Luka Brcic
Journal:  Oncologist       Date:  2018-08-03

Review 5.  Ceritinib: a Review in ALK-Positive Advanced NSCLC.

Authors:  Emma D Deeks
Journal:  Target Oncol       Date:  2016-10       Impact factor: 4.493

6.  Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

Authors:  Glenwood D Goss; Enriqueta Felip; Manuel Cobo; Shun Lu; Konstantinos Syrigos; Ki Hyeong Lee; Erdem Göker; Vassilis Georgoulias; Wei Li; Salih Guclu; Dolores Isla; Young Joo Min; Alessandro Morabito; Andrea Ardizzoni; Shirish M Gadgeel; Andrea Fülöp; Claudia Bühnemann; Neil Gibson; Nicole Krämer; Flavio Solca; Agnieszka Cseh; Eva Ehrnrooth; Jean-Charles Soria
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

7.  Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.

Authors:  D G Bebb; J Agulnik; R Albadine; S Banerji; G Bigras; C Butts; C Couture; J C Cutz; P Desmeules; D N Ionescu; N B Leighl; B Melosky; W Morzycki; F Rashid-Kolvear; Clin Lab; H S Sekhon; A C Smith; T L Stockley; E Torlakovic; Z Xu; M S Tsao
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

8.  Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma.

Authors:  Annamaria Catino; Andrea Misino; Anna Scattone; Lucia Caldarola; Stella Petroni; Antonio Logroscino; Elisabetta Sara Montagna; Gabriella Serio; Giovanni Simone; Domenico Galetta
Journal:  Transl Lung Cancer Res       Date:  2016-02

9.  Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?

Authors:  Giuseppe Lo Russo; Claudia Proto; Marina Chiara Garassino
Journal:  Transl Lung Cancer Res       Date:  2016-02

10.  Modular 3-cm uniportal video-assisted thoracoscopic left upper lobectomy with systemic lymphadenectomy.

Authors:  Qi Wang; Yi-Xin Cai; Yu Deng; Sheng-Ling Fu; Xiang-Ning Fu; Ni Zhang
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.